VIP Dosage: How Much to Take, When & How
Overview
Vasoactive Intestinal Peptide (VIP) is a 28-amino acid neuropeptide administered via nasal or injectable routes for research and investigational therapeutic purposes. Available dosing protocols range from 50 mcg per nostril (nasal) to 25–100 mcg via injection, with administration frequencies varying from once daily to four times daily depending on the route and clinical context.
VIP is not FDA-approved as a therapeutic agent in the United States and must be obtained through compounding pharmacies under physician supervision. This guide covers evidence-based dosing protocols based on clinical studies, observational data, and practical experience. This is educational content and not medical advice. Consult a qualified healthcare provider before starting VIP therapy.
Standard Dosing Protocol
Nasal Administration (Most Common)
Standard Dose:
- 50 mcg per nostril (100 mcg total per dose)
- Frequency: 4 times daily
- Total Daily Dose: 400 mcg
Administration Schedule:
- Morning: 50 mcg per nostril upon waking
- Midday: 50 mcg per nostril at lunch
- Evening: 50 mcg per nostril at dinner
- Bedtime: 50 mcg per nostril before sleep
This four-times-daily protocol is the most extensively studied and remains the standard of care in clinical literature, particularly for chronic inflammatory response syndrome (CIRS) and post-viral conditions.
Injectable Administration (Subcutaneous or Intramuscular)
Standard Dose Range:
- 25–100 mcg per injection
- Frequency: Once daily to twice daily
Typical Protocol:
- Conservative approach: 25–50 mcg once daily
- Standard approach: 50 mcg once or twice daily
- Higher-dose approach: 75–100 mcg once or twice daily
Injectable dosing offers greater flexibility and is preferred by some patients for compliance reasons, though local tissue irritation and systemic effects may occur at higher doses.
Dosing by Goal
VIP lacks rigorous human RCT evidence for most therapeutic claims, yet observational data and mechanistic studies suggest variable efficacy across different health outcomes. Dosing adjustments based on your primary goal are outlined below:
Anti-Inflammatory / Immune Modulation (Tier 2 Evidence)
Recommended Dose:
- Nasal: 50 mcg per nostril, 4 times daily (400 mcg/day)
- Injectable: 50 mcg once daily to 50 mcg twice daily
Rationale: VIP suppresses TNF-α, IL-1β, and other pro-inflammatory cytokines while promoting regulatory T-cell differentiation and inhibiting mast cell degranulation. The four-times-daily nasal protocol optimizes circulating VIP levels throughout the day.
Expected Timeline: 2–4 weeks for measurable immune modulation; 8–12 weeks for subjective symptom improvement.
CIRS / Mast Cell Activation (Tier 2 Evidence)
Recommended Dose:
- Nasal: 50 mcg per nostril, 4 times daily (400 mcg/day)
Rationale: CIRS and mast cell disorders show the strongest mechanistic alignment with VIP's anti-inflammatory and mast cell-stabilizing properties. Four daily doses maintain steady-state VIP levels.
Expected Timeline: 4–12 weeks for symptom reduction; discontinue if no improvement by 16 weeks.
Neurological / Cognitive Health (Tier 2 Evidence)
Recommended Dose:
- Nasal: 50 mcg per nostril, 3–4 times daily (300–400 mcg/day)
- Injectable: 50–75 mcg once or twice daily
Rationale: VIP promotes neuroprotection and neurogenesis in preclinical models. Three to four daily doses support circadian rhythm regulation and neuroendocrine function. Higher-dose approaches may be considered in advanced protocols.
Sleep & Circadian Health (Tier 2 Evidence)
Recommended Dose:
- Nasal: 50 mcg per nostril, 2–3 times daily, with emphasis on evening/bedtime dose
- Injectable: 50 mcg once daily in the evening
Rationale: VIP regulates circadian rhythms and SCN (suprachiasmatic nucleus) function. Concentrating doses toward evening may optimize sleep entrainment.
Sample Schedule:
- Morning: 50 mcg per nostril
- Evening (dinner): 50 mcg per nostril
- Bedtime: 50 mcg per nostril (critical dose)
Joint & Cartilage Health (Tier 3 Evidence)
Recommended Dose:
- Nasal: 50 mcg per nostril, 2–3 times daily (200–300 mcg/day)
- Injectable: 50 mcg once daily
Rationale: Lower VIP levels (30% reduction) are observed in osteoarthritis patients. Moderate dosing may help restore synovial fluid VIP concentrations without excessive systemic effects.
Expected Timeline: 8–16 weeks for subjective benefit; biomarker reduction (ADAMTS expression) likely requires 12+ weeks.
Cardiovascular / Pulmonary (Tier 2 Evidence)
Recommended Dose:
- Injectable: 50–100 mcg once or twice daily
- Nasal: 50 mcg per nostril, 3–4 times daily
Caution: VIP is a potent vasodilator and bronchodilator. Start at the lower end of the dosing range and titrate cautiously. Blood pressure monitoring is recommended during the first 2–4 weeks.
How to Administer
Nasal Administration (Spray or Powder)
-
Preparation:
- Ensure nasal passages are clear; gently blow nose before administration
- If nasal congestion is present, use saline rinse 5–10 minutes prior
- Keep the VIP container at room temperature
-
Technique:
- Tilt head slightly forward
- Insert nozzle into one nostril and depress spray firmly or inhale powder gently
- Repeat in the other nostril
- Breathe normally; do not sniff aggressively, as this may push VIP into the throat
- Remain upright for 1–2 minutes after administration
-
Common Issues:
- Nasal irritation or congestion: Use saline rinse before doses; consider every-other-day dosing if irritation persists
- Epistaxis (nosebleed): Space doses at least 4 hours apart; reduce frequency to 2–3 times daily
- Congestion from cold or allergies: Temporarily reduce to once or twice daily until passages clear
Injectable Administration (Subcutaneous or Intramuscular)
-
Preparation:
- Rotate injection sites to minimize tissue irritation (abdomen, thigh, upper arm, buttocks)
- Swab the injection site with an alcohol wipe; let dry for 5 seconds
- Allow the vial to reach room temperature if refrigerated
-
Technique:
- Use a 28–31 gauge needle for subcutaneous injection; 25–27 gauge for intramuscular
- Inject perpendicular to the skin; pinch the skin fold for subcutaneous routes
- Inject slowly over 5–10 seconds to minimize discomfort
- Withdraw needle straight out and apply gentle pressure with a clean cotton ball
-
Site Rotation Schedule:
- Monday: Right abdomen
- Wednesday: Left abdomen
- Friday: Right thigh
- Sunday: Left thigh
- Vary upper arm and buttocks as needed for longer protocols
-
Disposal:
- Place used needles in a FDA-approved sharps container
- Do not reuse needles; use a fresh needle for each injection
Cycling & Timing
VIP dosing protocols may benefit from strategic cycling to minimize tolerance and optimize receptor sensitivity, though human data on cycling schedules is limited.
Continuous Dosing Protocol (Standard)
Duration: 8–16 weeks without interruption
Best for: Initial therapy, acute inflammatory flares, post-viral syndromes
Advantages: Rapid establishment of therapeutic benefit, simplified compliance
Disadvantages: Potential receptor downregulation over time; may require dose escalation
Pulse (Intermittent) Protocol
Schedule: 5 days on, 2 days off (weekly cycle)
Duration: 8–12 weeks, then reassess
Example Week:
- Monday–Friday: 50 mcg per nostril, 4 times daily
- Saturday–Sunday: No VIP
Best for: Chronic conditions requiring long-term management, patients concerned about tolerance
Advantages: May preserve receptor sensitivity; lower cumulative monthly dose (~2,800 mcg vs. 4,000 mcg); potentially reduced side effects
Dose Escalation Protocol (Advanced)
Week 1–2: 50 mcg per nostril, 2 times daily (200 mcg/day) Week 3–4: 50 mcg per nostril, 3 times daily (300 mcg/day) Week 5+: 50 mcg per nostril, 4 times daily (400 mcg/day)
Best for: Patients with low baseline VIP or slow initial response
Caution: Monitor for hypotension, facial flushing, and nausea during escalation
Maintenance After Initial Response
Once symptom improvement is observed (typically 4–8 weeks), consider dose reduction:
- Maintenance Phase: 50 mcg per nostril, 2–3 times daily (200–300 mcg/day)
- Duration: Indefinite or until symptom stability warrants tapering
- Taper: Reduce by one dose every 1–2 weeks if discontinuing
Beginner vs. Advanced Dosing
Beginner Protocol (First-Time Users)
Duration: Weeks 1–4
Nasal Dosing:
- Week 1: 50 mcg per nostril, twice daily (morning and evening)
- Week 2: 50 mcg per nostril, twice daily (continue; assess tolerance)
- Week 3: Add midday dose → 50 mcg per nostril, 3 times daily
- Week 4: Add bedtime dose → 50 mcg per nostril, 4 times daily (if tolerated)
Injectable Dosing:
- Start: 25 mcg once daily, subcutaneous
- Week 2: Assess tolerance; increase to 25 mcg once daily intramuscular if preferred
- Week 3: Increase to 50 mcg once daily
- Week 4+: Consider 50 mcg twice daily if indicated
Monitoring:
- Keep a daily log of side effects, energy, mood, and specific symptoms
- Measure blood pressure before and 15 minutes after the first dose
- Contact your prescriber if severe hypotension (dizziness, syncope), persistent nausea, or severe nasal irritation develops
Advanced Protocol (Experienced Users or Higher-Dose Therapy)
Duration: Weeks 8+
Nasal Dosing:
- Maintain or escalate to 50 mcg per nostril, 4 times daily (400 mcg/day)
- Consider pulse dosing (5 on, 2 off) after 8 weeks of continuous therapy
- Optional: Increase to 75 mcg per nostril if inflammation remains severe and tolerance is excellent (total 300 mcg/dose, 1,200 mcg/day) — not standard; requires physician approval
Injectable Dosing:
- 50–100 mcg once or twice daily, depending on response and tolerability
- Consider intramuscular administration if superior systemic effect is needed
- Monitor blood pressure weekly, especially if dosing twice daily
Monitoring:
- Continue symptom logs; track inflammatory biomarkers (CRP, TNF-α) if available
- Reassess goals every 12 weeks; taper if goals are met or plateau after 16 weeks
- Consider VIP receptor desensitization after 12+ weeks of continuous dosing; a 1–2 week break may restore responsiveness
Common Dosing Mistakes
1. Skipping Doses or Inconsistent Timing
Problem: Inconsistent administration disrupts steady-state VIP levels, reducing efficacy.
Solution: Set phone reminders for all four daily doses (if nasal) or inject at the same time each day. Use a pill organizer or dosing calendar.
2. Administering Nasal Spray While Lying Down
Problem: Gravity causes VIP to drain into the throat and GI tract, reducing nasal bioavailability.
Solution: Remain upright for at least 2 minutes after nasal administration.
3. Over-Aggressive Sniffing After Nasal Administration
Problem: Sniffing or inhaling sharply pushes VIP into the nasopharynx and oropharynx, reducing absorption.
Solution: Use gentle nasal breathing; do not forcefully sniff or inhale.
4. Increasing Dose Without Monitoring Blood Pressure
Problem: VIP is a potent vasodilator; rapid dose escalation risks symptomatic hypotension.
Solution: Check blood pressure before and 15 minutes after doses during the first 2–4 weeks, especially if increasing from 2 to 4 daily doses.
5. Starting at Maximum Dose (400 mcg/Day)
Problem: High initial doses increase the risk of facial flushing, nausea, lightheadedness, and treatment discontinuation.
Solution: Always use a beginner protocol; titrate from 100–200 mcg/day upward over 2–4 weeks.
6. Expecting Immediate Results
Problem: VIP's anti-inflammatory and immunomodulatory effects require 4–8 weeks to manifest subjectively.
Solution: Commit to 8–12 weeks of consistent dosing before assessing efficacy. Inflammatory biomarkers (CRP, cytokines) may improve before subjective symptoms.
7. Continuing at High Doses Beyond 12 Weeks Without Reassessment
Problem: Receptor downregulation and diminishing returns may occur; dose escalation becomes necessary.
Solution: Assess response every 8–12 weeks. If plateaued, consider a 1–2 week break or transition to pulse dosing.
8. Not Cycling Injection Sites
Problem: Repeated injection at the same site causes tissue irritation, scarring, and reduced absorption.
Solution: Rotate injection sites systematically (see "How to Administer" section above).